Medidata Solutions Inc

Find Ratings Reports
MDSO : NASDAQ : Technology
$51.9 | %
Today's Range: 0.0 - 0.0
Avg. Daily Volume: 496600.0
01/17/17 - 4:00 PM ET

Financial Analysis


MEDIDATA SOLUTIONS INC's gross profit margin for the third quarter of its fiscal year 2016 is essentially unchanged when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. MEDIDATA SOLUTIONS INC is extremely liquid. Currently, the Quick Ratio is 3.60 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.

At the same time, stockholders' equity ("net worth") has greatly increased by 25.47% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q3 FY16 Q3 FY15
Net Sales ($mil)120.06103.11
EBITDA ($mil)18.8513.86
EBIT ($mil)14.9311.1
Net Income ($mil)7.364.68


Balance Sheet Q3 FY16 Q3 FY15
Cash & Equiv. ($mil)330.07287.31
Total Assets ($mil)785.77683.77
Total Debt ($mil)259.85249.75
Equity ($mil)379.11302.15


Profitability Q3 FY16 Q3 FY15
Gross Profit Margin78.8580.53
EBITDA Margin15.6913.43
Operating Margin12.4310.77
Sales Turnover0.560.56
Return on Assets3.171.72
Return on Equity6.583.9
Debt Q3 FY16 Q3 FY15
Current Ratio3.813.77
Debt/Capital0.410.45
Interest Expense4.224.04
Interest Coverage3.542.75


Share Data Q3 FY16 Q3 FY15
Shares outstanding (mil)57.655.35
Div / share0.00.0
EPS0.130.08
Book value / share6.585.46
Institutional Own % n/a n/a
Avg Daily Volume508228.0383201.0

Valuation


BUY. MEDIDATA SOLUTIONS INC's P/E ratio indicates a significant premium compared to an average of 94.54 for the Health Care Technology industry and a significant premium compared to the S&P 500 average of 25.49. For additional comparison, its price-to-book ratio of 7.93 indicates a significant premium versus the S&P 500 average of 2.84 and a significant premium versus the industry average of 5.25. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. Upon assessment of these and other key valuation criteria, MEDIDATA SOLUTIONS INC proves to trade at a premium to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
MDSO 118.57 Peers 94.54   MDSO 38.24 Peers 23.10

Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.

MDSO is trading at a significant premium to its peers.

 

Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

MDSO is trading at a significant premium to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
MDSO 42.59 Peers 41.03   MDSO 0.34 Peers 0.69

Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.

MDSO is trading at a premium to its peers.

 

Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

MDSO trades at a significant discount to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
MDSO 7.93 Peers 5.25   MDSO 109.52 Peers 29.11

Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

MDSO is trading at a significant premium to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

MDSO is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
MDSO 6.86 Peers 5.53   MDSO 14.34 Peers 23.39

Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

MDSO is trading at a premium to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

MDSO significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades